Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: simuni t. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Neuronal α-Synuclein Disease Stage Progression over 5 Years.
Simuni T, Gochanour C, Nair AR, Brumm MC, Coffey C, Poston KL, Chahine LM, Weintraub D, Tanner CM, Gonzalez-Latapi P, Kopil CM, Xiao Y, Chowdhury S, Dam T, Pagano G, Stephenson D, Siderowf A, Dunn B, Marek K; NSD Working Group the Parkinson's Progression Markers Initiative. Simuni T, et al. Mov Disord. 2025 Apr 30. doi: 10.1002/mds.30191. Online ahead of print. Mov Disord. 2025. PMID: 40302527
Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease.
Mammen JR, Adams JL, Mangrum R, Xiao Y, Barbosa W, Tyo M, Redmond C, Carter C, Cifelli K, Cifelli R, Maruzo H, Meeker J, Shultz G, Thomas C, Bale C, Davies E, Kopil CM, Marras C, Mestre T, Morel T, Simuni T, Stebbins GT, Weintraub D, Stephenson D. Mammen JR, et al. Among authors: simuni t. NPJ Parkinsons Dis. 2025 Apr 3;11(1):65. doi: 10.1038/s41531-025-00907-2. NPJ Parkinsons Dis. 2025. PMID: 40175369 Free PMC article.
LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization.
Chahine LM, Lafontant DE, Choi SH, Iwaki H, Blauwendraat C, Singleton AB, Brumm MC, Alcalay RN, Merchant K, Nudelman KNH, Dagher A, Vo A, Tao Q, Venuto CS, Kieburtz K, Poston KL, Bressman S, Gonzalez-Latapi P, Avants B, Coffey C, Jennings D, Tolosa E, Siderowf A, Marek K, Simuni T; Parkinson’s Progression Markers Initiative. Chahine LM, et al. Among authors: simuni t. Brain Commun. 2025 Mar 6;7(2):fcaf103. doi: 10.1093/braincomms/fcaf103. eCollection 2025. Brain Commun. 2025. PMID: 40114783 Free PMC article.
Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study.
Ellenbogen AL, Poewe W, Espay AJ, Simuni T, Gurevich T, Yardeni T, Lopes N, Sasson N, Case R, Stocchi F; BeyoND study group. Ellenbogen AL, et al. Among authors: simuni t. Parkinsonism Relat Disord. 2025 Mar;132:107293. doi: 10.1016/j.parkreldis.2025.107293. Epub 2025 Jan 16. Parkinsonism Relat Disord. 2025. PMID: 39884033 Free article. Clinical Trial.
271 results